Search

In the diagnosis of lung cancer, tissue and cytologic specimens are needed for confirmation of the diagnosis, elucidation of the histologic type of lung cancer, determination of the extent of the cancer, and increasingly also for the molecular biological investigations required for the planning of drug therapy. The site and method of specimen collection are chosen multidisciplinarily on the basis of imaging studies, taking the clinical picture and patient safety into consideration. High-quality and quantitatively representative specimens are required for molecular biological analyses, and assessment of the response to drug therapy or modifying the treatment may require a new sample, which can be a tissue or cytologic specimen or a liquid biopsy.

Besides histological classification of lung cancers, molecular biological examination of tumors is part of modern diagnostics of lung cancers, and cancer therapies are based on molecular biological diagnosis. Current laboratory technique enables the examination of many mutations as part of standard routine diagnosis, necessitating functional multidisciplinary collaboration, with the pathologist playing a central role in the handling of the specimens. In the future, especially pathologists, pulmonary specialists and oncologists are expected to need a good command of molecular biological data on lung cancer, but basic knowledge will be required also from other physicians working with lung cancer patients.

Acute or subactute pulmonary damage can be either idiopathic or resulting from a known cause. The most common histologic types are diffuse acute alveolar damage (DAD) and organizing pneumonia (OP). Various kinds of infection, pulmonary drug reactions or acute exacerbations of interstitial lung diseases may cause DAD, often requiring intensive care. High-resolution computed tomography (HRTT) of the lungs is the most important diagnostic examination. Surgical lung biopsy is performed for few patients.

Nearly half of all lung cancers are adenocarcinomas falling into various subtypes. Other common types of lung cancer include squamous cell carcinoma and small cell carcinoma. The pathogenesis and molecular biology of lung cancer has been the subject of considerable research over the last few years, and new pharmacologic therapies have been developed. The histological classification of lung adenocarcinomas has been revised in 2011, and is already becoming established in replacing the WHO classification. The aim of the new classification is to make the diagnostics of lung cancer and assessment of treatment options more precise.